220 results about "Uterine bleeding" patented technology

A first method for ultrasound uterine medical treatment includes obtaining an end effector having an ultrasound medical-treatment transducer assembly, identifying a blood vessel which supplies blood to a portion of the uterus, and medically treating the blood vessel with ultrasound from the transducer assembly to substantially seal the blood vessel to substantially stop the supply of blood from the blood vessel to the portion of the uterus. In one example, shrinkage of a uterine fibroid is accomplished through use of the end effector endoscopically inserted into the uterus. A second method for ultrasound uterine medical treatment includes endoscopically inserting the end effector into the uterus and medically treating the endometrium lining with ultrasound from the transducer assembly to ablate a desired thickness of at least a portion of the endometrium lining to substantially stop abnormal uterine bleeding from the endometrium lining.

The invention is directed to an intravaginal uterine artery occlusion device for treating uterine disorders such as fibroids, dysfunctional uterine bleeding, postpartum hemorrhage and the like. A occlusion device has a cervical receptacle or cap with an open distal end for receiving the patient's uterine cervix and an elongated shaft having a distal end secured to the closed proximal end of the cervical receptacle and an inner lumen extending to the distal end of the elongated shaft. The patient's uterine cervix is held within the interior of the receptacle by the application of a vacuum to the interior of the receptacle through the inner lumen of the shaft or otherwise, while the leading edge(s) of the cervical receptacle press against the patient's vaginal fornix to occlude an underlying or adjacent uterine artery. At least one blood flow sensor may be provided on the leading edge of the receptacle to aid in locating a uterine artery and to monitor blood flow through the located uterine artery.

Progesterone antagonists and SPRM are useful to prepare a medication for the treatment or the prophylaxis of excessive uterine bleeding in women with spontaneous or iatrogenic coagulation disorders such as thrombopenia, coagulation factor deficiency or anti-coagulant therapy. Treatment will last from 1 day to 180 days.

A progesterone receptor modulator of the structure

is provided. Use of compositions containing this compound for contraception, hormone replacement therapy, treating hormone-dependent disease, synchronizing estrus, treating dysmenorrhea, treating dysfunctional uterine bleeding, inducing amenorrhea, or treating symptoms of premenstrual syndrome and premenstrual dysphoric disorder in a mammal are described.

A method and apparatus of occluding a lumen of a body cavity, more preferably, the lower uterine segment and/or cervix of a female patient is provided that results in a significant reduction or complete elimination of uterine bleeding, thereby providing a treatment option for conditions such as menorrhagia or dysmenorrhea.

The invention belongs to the technical field of health care products, in particular to a method for preparing deer skin gelatin. The method for preparing deer skin gelatin is characterized by comprising the following steps: (1) soaking; (2) removing fur and oil; (3) extracting gelatin liquid; (4) concentrating and purifying; (5) injecting gelatin into a die and placing concentrated and purified deer skin gelatin into a die disk; after the gelatin is solidified, taking out, cutting into blocks and airing or placing the gelatin into an oven at 70-90 DEG C to dry; and packaging in vacuum to prepare a finished product. The invention relates to the method for preparing the deer skin gelatin. The method can process and produce the deer skin gelatin throughout the year, and has simple process without damaging nutrition components of deer skin; and the prepared deer skin gelatin is a health care product with high nutrition components and has the assistant treating effect on diseases of premature ejaculation, kidney deficiency and spermatorrhea of men, leucorrhea, uterine bleeding and wound bleeding of women, and the like.

The invention provides a product and a product composition for improving sub-health status. The product and the product composition comprise maca and oyster peptides. The composition provided by the invention is unique and reasonable in formula and can be granules, powder, capsules, tablets or the like. The product and the product composition have the functions of adjusting the secretion of hormones, improving the sleeping quality, enhancing the memory ability, reducing blood fat, inhibiting platelet aggregation, improving hyperglycemia symptoms, improving the immunity of human bodies, promoting metabolism and the like, obvious curative effects on climacteric syndrome, puberty essential uterine bleeding, and antenatal or postpartum weakness of women and a very obvious effect on fatigue caused by working pressure and life pressure as well as the physiology regression of middle-aged and aged people. The maca and oyster in the composition are food eaten for thousands of years, and the toxic and side effects of the maca and oyster are not found. The product and the product composition can also contain tartary buckwheat so as to give full play to a relatively good anticancer effect.

The invention relates to a medicine adopting deerskin as a raw material and a preparation method thereof, in particular to a health product or food processed by deerskin and a preparation method thereof. Deerskin ointment is prepared by deerskin, motherwort, astragalus root, Chinese date, angelica sinensis, sugar candy, yellow wine, sweet osmanthus honey and agal-agal. The invention aims to solve the problems existing in the aspects of waste, insufficient development and utilization, difficult absorption and utilization by human bodies, and the like of a plurality of prior deerskin resources. The deerskin ointment has the obvious effect on symptoms of woman leucorrhoea, uterine bleeding, kidney deficiency, spermatorrhea, skin ulcer breeding, and the like.

A composite Chinese medicine in the form of dripping pill and soft capsule for treating palpitation, insomnia, hypomnesia, anorexia, hematochezia, uterine bleeding, morbid leukorrhea, etc, and its preparing process are disclosed.

A medical balloon, implantable in human tissue, of unitary silicone construction. The balloon is self-sealing upon removal of an inflation implement. The balloon device comprises a molded valve portion which is dip-coated in a silicone dispersion to create a balloon wall around and integral with the valve portion. Preferably, both the valve portion and the balloon wall are comprised of the same silicone material. The dipping process, combined with a vulcanizing process, creates a laminar wall which is strong and resistant to separation during inflation. The balloons may be used in for the treatement of urinary incontinence or vesicoureteral reflux, alternative procedures such as emboliztion or blocking of veins or arteries to accomplish the treatement of enlarged blood vessels in the brain or for treating severe uterine bleeding.

The invention relates to an application of the fusion proteins FP1-FP8 of VEGF receptors on the treatment of the diseases relating to angiogenesis. The diseases relating to the angiogenesis includes autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, vasculitis, systemic sclerosis and other diseases caused by the angiogenesis such as bronchial asthma, obesity, nasal polyps, rhinitis, liver cirrhosis, endometriosis, uterine bleeding, warts, scars and ovarian cysts, etc.

A Chinese medicine in the form of oral liquid for treating menalgia, menoxenia, uterine bleeding, morbid leukorrhea, etc is prepared from 19 Chinese-medicinal materials including Taihe chicken, ginseng, antler, Chinese angelica root, etc through conventional process.

The invention relates to a traditional Chinese medicine combination for treating gynecologic functional uterine bleeding diseases, which comprises the following raw medicinal materials in portions by weight: 900-1100 portions of red paeonia, 900-1100 portions of motherwort, 200-400 portions of pseudo-ginseng, 900-1100 portions of agrimony, 500-700 portions of charred radix sanguisorbae and 500-700 portions of charred pollen typhae. The preparation method of the traditional Chinese medicine combination comprises the following steps: extracting from the red paeonia and the pseudo-ginseng with 80% ethanol, extracting from the motherwort, the agrimony, the charred radix sanguisorbae and the charred pollen typhae with water, and finally preparing the traditional Chinese medicine combination byan appropriate process. The invention also relates to a capsule quality control method of the traditional Chinese medicine combination, which comprises an identification step and a content determination step, wherein in the identification step, identification is carried out by using red paeonia control medicinal materials, paeoniflorin controls, pseudo-ginseng control medicinal materials, agrimony control medicinal materials, motherwort control medicinal materials and stachydrine hydrochloride controls based on a thin-layer chromatography; and in the content determination step, the content ofthe red paeonia should be not less than 12.0mg per capsule (measured by penoniflorin, C23H28O11 and determined by the red paeonia). The traditional Chinese medicine combination has the advantages of high hemostasis speed, good effect and the like. The capsule quality control method can conveniently and visually identify the preparation and can well ensure the effect of the traditional Chinese medicine combination.

A Chinese medicine for treating uterine bleeding is prepared from 7 Chinese-medicinal materials including rehmannia root, rhubarb, sanguisorba root, notoginseng, etc. Its preparing process is also disclosed.

The invention discloses a boxthorn leaf traditional Chinese medicine health tea for preventing and curing lung-kidney yin deficiency, which comprises the following bulk pharmaceutical chemicals in parts by weight: 100-200 parts of boxthorn leaf, 10-20 parts of fried gorgon fruit, 10-20 parts of angelica sinensis, 10-20 parts of peach kernel, 10-20 parts of radix ophiopogonis, 10-20 parts of codonopsis pilosula, 10-20 parts of schisandra chinensis, 10-20 parts of radix polygonati officinalis, 10-20 parts of adenophora elata, 10-20 parts of rhizoma curculiginis, 10-20 parts of root of rehmannia, 10-20 parts of prepared fleece flower root, 10-20 parts of leonurus, 10-20 parts of glossy privet fruit, 10-20 parts of sealwort, and 10-20 parts of poria. Due to the effects of the boxthorn leaf, such as being cool in nature, bitter but sweet in taste and non-toxic, and being capable of tonifying essence, clearing heat, quenching thirsty, relieving rheumatic pains, improving eyesight, curing consumptive disease and fever, polydipsia, hot eyes and ache, uterine bleeding and morbid leucorrhoea, carbuncle and the like, a systematic study is carried out on the boxthorn leaf by adopting modern technology, the prepared boxthorn tea has good taste and rich fragrance, has no odor, can be accepted by the consumers. Traditional Chinese medicine which has mild property and flavor and is beneficial to lung and spleen and is used for preventing and curing kidney deficiency is added into the tea, therefore, the tea has obvious effect on sub health people with symptom of lung-kidney yin deficiency.

The invention relates to an oral preparation of consolidating-yin decoction medicine, which is prepared with ginseng and other seven Chinese medicines mainly for treating yin deficiency and emission, turbid leucorrhea and dribbling and non-consolidation of menses resulted from deficiency, and the preparation method thereof. The oral preparation is prepared according to the conventional processes and utilizing the mixed extracts as raw materials, such as ginseng, old land, Chinese yam, cornus officinalis, dodder, milkwort, schisandra chinensis and baked licorice, together with vector or excipient which are utilized as matrix and acceptable in pharmacy. The preparation has the effects of reinforcing kidney and regulating menstruation, and mainly treats yin deficiency and frequent diarrhea, turbid leucorrhea and dribbling and non-consolidation of menses resulted from deficiency. The long-term clinical application of the prescription shows that the preparation has good effects on menoxenia, dysfunctional uterine bleeding, infertility, amenorrhea and nocturnal emission, etc.

The invention relates to a enzyme predicted to be a serine protease, which is specifically expressed in association with embryo implantation and placentation in pregnant uterus. The enzyme of the invention is useful in the evaluation of fertility and monitoring of early pregnancy, placental development and function, fetal development, parturition, and conditions such as pre-eclampsia, intrauterine growth restriction, early abortion, abnormal uterine bleeding, endometriosis, and cancers, and may provide a potential target for contraception. It may also be important in diseases of the heart, testis or ovary, and may play a role in muscle function, including cardiac muscle, skeletal muscle, lung and the diaphragm. In addition the enzyme of the invention is useful in the screening of candidate drugs for fertility control or for treatment of fertility-related disorders.

The invention discloses a Chinese medicinal composition for treating functional uterine bleeding, which selects the Chinese medicinal herbs with effects of tonifying the kidney, replenishing qi, eliminating of blood stasis and stopping blood, i.e. cassia bark, medlar, largehead atractylodes rhizome, India madder root, poria, himalayan teasel root, garden burnet root, Chinese arborvitae twig, common cephalanoplos herb, Chinese leek root, ginseng and Chinese mugwort leaf, according to the disease causes of the functional uterine bleeding and carries out scientific compatibility. The invention provides capsules for more effectively treating functional uterine bleeding. The clinical application proves that the capsules of the invention have exact curative effect on the patients suffering from functional uterine bleeding, has short administration time, less dosage, quick response, short time of stopping blood and high hemoglobin recovery rate and is valuable to be clinically popularized and applied.

An inflatable uterine device to control uterine bleeding, comprising an inflatable balloon (10) and a hose (11) connecting the balloon to a fluid source. The fluid source comprises an open container (12). A first end of the hose can be integrally connected to the inflatable balloon and a second end of the hose can be integrally connected to the container, and a suspension means (14; 15) is provided at the second end of the hose. A method for producing an inflatable uterine device includes the following steps. Feeding an upper film (18) of plastic material from a first roll (17), feeding a lower film (20) of plastic material from a second roll (19), joining said upper film (18) and said lower film (20) along contour lines forming an inflatable balloon (10), a container (12) and a hose (11) connecting the balloon to the container in an open fluid path, said container (12) having an open end formed by the absence of a joint between said upper film (18) and said lower film (20), and cutting the films outside said contour lines.

The invention relates to C27 spirostane-type steroidal saponins isolated from Ypsilandra, Trillium and Paris and their preparation method, as well as their application in the preparation of drugs for treating hemorrhagic diseases, and application in the preparation of drugs for treating dysfunctional uterine bleeding, and the preparation of functional daily chemical products and health products. The materials used in a method of the invention are easy to obtain, the method is simple and easily operable, biological experiments of the compound produced show that the compound can induce platelet aggregation activity and hemostatic activity significantly.

The invention discloses a medicine for nursing functional uterine bleeding and a preparation method thereof and belongs to the field of traditional Chinese medicines. The medicine comprises effective ingredients composed of the following raw materials in parts by weight: 80 to 110 parts of radix paeoniae alba, 70 to 90 parts of nodus nelumbinis rhizomatis, 65 to 85 parts of fructus lycii, 50 to 70 parts of sanguisorba officinalis, 45 to 60 parts of rhizoma atractylodis macrocephalae, 40 to 55 parts of radix rubiae, 35 to 50 parts of cortex lycii radicis, 30 to 48 parts of folium artemisiae argyi, 28 to 45 parts of ligusticum wallichii, 25 to 40 parts of pericarpium citri reticulatae viride, 22 to 36 parts of cuttle bone, 18 to 30 parts of angelica sinensis, 15 to 25 parts of dragon bone, 12 to 22 parts of concha ostreae, 8 to 18 parts of marmor serpentinatum, and 4 to 10 parts of hair. The medicine is careful in material selection, is prepared based on the principles of tonifying kidney, smoothening Chong channel, stopping bleeding and regulating menstruation, strengthening spleen control liver, soothing liver and cooling blood, nourishing Yin and dissipating stasis, and can adjust the endocrine and central nervous system according to the etiologies of Qi depression and insufficiency of the spleen, liver disorders, deficiency of Chong and Ren chanels and blood heat which cause functional uterine bleeding; and the medicine is good in absorption effect, and applicable to nursing of functional uterine bleeding.

The invention discloses a pharmaceutical preparation prepared from fresh motherwort and fresh aloe and a preparation method thereof. The pharmaceutical preparation is characterized by being prepared from the following raw medicines in parts by weight: 12-40 parts of fresh motherwort and 3-270 parts of fresh aloe. The pharmaceutical preparation disclosed by the invention has the functions of promoting blood circulation to activate collaterals and dispelling toxins to beautify the face, and has an effect on improving dysmenorrhea, amenorrhea, uterine bleeding, dizziness due to deficiency of blood, palpitation and intestine dryness constipation.

The invention discloses an application of catalpol in preparing ovarian aging resisting medicaments. The catalpol can treat various ovarian aging diseases, and particularly has obvious effects on polycystic ovarian syndrome, dysfunctional uterine bleeding, premature ovarian failure or menopause syndrome and the like. According to the application, the catalpol is prepared into oral medicaments, transdermal medicaments or injections for treating ovarian failure diseases.